Literature DB >> 16186263

Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values.

Bruce W Bode1, Sherwyn Schwartz, Harrison A Stubbs, Jon E Block.   

Abstract

OBJECTIVE: The purpose of this study was to generate normative values for periods of euglycemia as well as for daily patterns of glycemic excursions in patients with type 1 and type 2 diabetes monitored continuously for a maximum period of 21 days and blinded to glucose levels. RESEARCH DESIGN AND METHODS: This was a multicenter, prospective observational study in which 101 consecutive patients with type 1 (n = 60) or type 2 (n = 41) diabetes underwent blinded continuous glucose monitoring. Serial glucose measurements were divided into periods of euglycemia (70-180 mg/dl), hyperglycemia (>180 mg/dl), and hypoglycemia (<70 mg/dl). The proportions of time patients were hypoglycemic, euglycemic, and hyperglycemic and the total areas under the curves (AUCs) were determined.
RESULTS: During the observation period the 101 subjects contributed an average 287 +/- 132 h of continuous glucose values. Subjects remained in the euglycemic range for approximately 63% of the total day, were hypoglycemic 8%, and were hyperglycemic 29%. Hypoglycemia was more prevalent nocturnally (11 vs. 7%) and hyperglycemia diurnally (31 vs. 25%). Compared with subjects with type 2 diabetes, type 1 diabetic subjects had more frequent hypoglycemic episodes per day (2.1 vs. 1.0; P < 0.001) that were of longer duration (1.1 vs. 0.7 h; P < 0.0001), reflecting a greater number of hours per day in the hypoglycemic range (2.3 vs. 1.0 h; P < 0.0001). The mean hypoglycemic AUC values were >150% higher for type 1 compared with type 2 diabetic subjects (41 vs. 16, respectively; P < 0.0001).
CONCLUSIONS: These normative data will assist in study and sample size planning for future investigations of continuous glucose monitoring and allow for qualitative comparisons with trials of therapeutic interventions aimed at reducing the occurrence of glycemic excursions.

Entities:  

Mesh:

Year:  2005        PMID: 16186263     DOI: 10.2337/diacare.28.10.2361

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  40 in total

1.  Association of glucose levels and glucose variability with mood in type 1 diabetic patients.

Authors:  N Hermanns; C Scheff; B Kulzer; P Weyers; P Pauli; T Kubiak; T Haak
Journal:  Diabetologia       Date:  2007-03-17       Impact factor: 10.122

Review 2.  Early diabetic neuropathy: triggers and mechanisms.

Authors:  Maxim Dobretsov; Dmitry Romanovsky; Joseph R Stimers
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 3.  Clinical requirements for closed-loop control systems.

Authors:  William L Clarke; Eric Renard
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

4.  Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.

Authors:  Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Aaron Winn; Parmida Zarei; Michael O'Grady; Elbert S Huang
Journal:  Diabetes Care       Date:  2018-04-12       Impact factor: 19.112

5.  Numerical simulation of the effect of rate of change of glucose on measurement error of continuous glucose monitors.

Authors:  Marc B Taub; Thomas A Peyser; J Erik Rosenquist
Journal:  J Diabetes Sci Technol       Date:  2007-09

6.  A benchtop closed-loop system controlled by a bio-inspired silicon implementation of the pancreatic beta cell.

Authors:  Nick Oliver; Pantelis Georgiou; Desmond Johnston; Christofer Toumazou
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

7.  Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals.

Authors:  Guido Freckmann; Sven Hagenlocher; Annette Baumstark; Nina Jendrike; Ralph C Gillen; Katja Rössner; Cornelia Haug
Journal:  J Diabetes Sci Technol       Date:  2007-09

8.  Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.

Authors:  Nathan C Geething; Wayne To; Benjamin J Spink; Michael D Scholle; Chia-wei Wang; Yong Yin; Yi Yao; Volker Schellenberger; Jeffrey L Cleland; Willem P C Stemmer; Joshua Silverman
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

9.  Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial.

Authors: 
Journal:  Diabetes Care       Date:  2009-10-16       Impact factor: 19.112

10.  Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.

Authors:  Denis Raccah; Véronique Sulmont; Yves Reznik; Bruno Guerci; Eric Renard; Hélène Hanaire; Nathalie Jeandidier; Marc Nicolino
Journal:  Diabetes Care       Date:  2009-09-18       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.